The FDA sent another warning to an Intas Pharmaceuticals plant in India, where investigators imposed import bans in late 2022 after finding shredded quality control documents doused in acid.

Janssen is recommending physicians withhold prescribing its pulmonary arterial hypertension drug because Philips Respironics is discontinuing the only approved delivery system for the drug.

Mark Cuban Cost Plus Drug Co. is teaming up with PharmcoRx, a pharmacy services business, to expand its pharmacy affiliate network. 

West Reading, Pa.-based Reading Hospital is planning to open a full-service retail pharmacy Nov. 29 in Wyomissing, Pa., according to Lehigh Valley Business.

Antiseizure medications made of levetiracetam and clobazam might cause a rash that can quickly injure organs and hospitalize patients, the FDA said Nov. 28. 

A popular class of Type 2 diabetes and weight management drugs is gaining the attention of women going through menopause who want to lose weight, The New York Times reported Nov. 27.

The FDA approved Ogsiveo (nirogacestat), the first drug indicated for locally aggressive, noncancerous tumors, on Nov. 27. 

Mark Cuban Cost Plus Drug Co. has partnered with digital health company Expion Health in an effort to tackle the rising costs of specialty drugs.

Genesis Medical Center-Dewitt, a MercyOne-owned hospital in Iowa, bought a local pharmacy to include in its network, Our Quad Cities reported Nov. 27. 

Eli Lilly's Mounjaro helped patients lose weight more effectively than Novo Nordisk's Ozempic, according to a preprint study that included more than 40,000 patients. 

Exela Pharma Sciences, an injectable drug company, is recalling more than 415,000 drug vials in a Class I recall because of a possible presence of silicone, according to the FDA. 

The fill rate of antibiotics for bacterial infections from respiratory syncytial virus surpassed the previous season's trend, indicating an unusually early RSV season. 

Surgeons and health system leaders are voicing concerns about the unknown long-term risks of glucagon-like peptide-1 receptor agonists, such as Ozempic, Wegovy and Saxenda. 

The FDA issued a final rule Nov. 21 that will require drugmakers to clearly state side effects and contraindications in direct-to-consumer advertisements. The rule is effective May 20, 2024. 

There's been a slight slowdown in reports of new drug shortages before the winter holiday season, but six medications recently entered the list of ongoing shortages, which include about 300 drugs. 

Seven senators are questioning why Sanofi and AstraZeneca underestimated the demand for Beyfortus, the first pediatric drug approved for respiratory syncytial virus. 

Timber Pharmaceuticals filed for Chapter 11 bankruptcy Nov. 17. 

Leigh Briscoe-Dwyer, PharmD, is mentoring the next generation of pharmacists as she pulls on her years of experience, according to a Nov. 17 article from Binghamton (N.Y.) University. 

The FDA approved CorMedix's Defencath Nov. 15, marking it the first and only catheter lock solution for catheter-related bloodstream infections. 

An FDA panel is urging Acrotech Biopharma to accelerate research into the efficacy of two blood cancer drugs brought to market via the agency's accelerated approval pathway.